| Private Placement / Financing Transactions
Zenas: The company raised $200 million of Series C venture funding in a deal led by Delos Capital, SR One Capital Management and New Enterprise Associates on May 7, 2024. Fairmount Funds Management, Enavate Sciences, Longitude Capital, Vivo Capital, Lepu Biopharma, Pivotal BioVenture Partners, Quantum Ventures, Wellington Management, Rock Springs Capital, Superstring Capital Management, Federated Hermes and ArrowMark Partners also participated in the round. The company is a clinical-stage biopharmaceutical business developing inflammation and immunology (I&I) directed therapies.
Bluejay Therapeutics: The company raised $182 million of Series C venture funding in a deal led by Frazier Lifesciences Acquisition on May 9, 2024. Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital Partners, RA Capital Management, RiverVest Venture Partners, Octagon Capital Advisors, T. Rowe Price, Wellington Management, Novo Holdings and other undisclosed investors also participated in the round. The company is a developer of therapeutic treatments for serious viral and liver diseases.
Attovia: The company raised $105 million of Series B venture funding in a deal led by The Goldman Sachs Group on May 9, 2024. Illumina Ventures, Frazier Healthcare Partners, venBio, Nextech Ventures, EcoR1 Capital, Marshall Wace, Logos Capital, Redmile Group and Cormorant Asset Management also participated in the round. The company is a developer of a biotherapeutics pipeline designed for immune-mediated disease and oncology.
Nectero Medical: The company raised $96 million in Series D venture funding in a deal led by Norwest Venture Partners on May 10, 2024, putting the company’s pre-money valuation at $74 million. Boston Scientific, Cadence Healthcare Ventures, Aphelion Capital, BioStar Capital and other undisclosed investors also participated in the round. The company is an operator of a clinical-stage biotechnology business intended to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms.
R3 Vascular: The company raised $87 million of Series B venture funding from Deerfield Management, 415 Capital and other undisclosed investors on May 9, 2024. The company is a developer and manufacturer of metallic stents designed to treat peripheral arterial diseases.
Aardvark Therapeutics: The company raised $85 million of Series C venture funding in a deal led by Decheng Capital on May 9, 2024. Vickers Venture Partners, FPWR, LG Technology Ventures, SymBiosis Capital Management, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, Cormorant Asset Management, Surveyor Capital, Cantor Fitzgerald, SilverArc Capital Management and Prader-Willi Syndrome Association also participated in the round. The company is a developer of small molecule therapeutics designed for the treatment of obesity and rare genetic metabolic diseases.
Rad AI: The company raised $50 million of Series B venture funding in a deal led by Khosla Ventures on May 7, 2024, putting the company’s pre-money valuation at $222 million. Alpha Partners, Gradient Ventures, Kickstart Fund, OCV Partners, ARTIS Ventures, Santa Barbara Venture Partners, Hyperlink Ventures and WiL (World Innovation Lab) also participated in the round. The company is a developer of an AI-based report generation platform designed to automate repetitive tasks for radiologists.
Prologue: The company raised $50 million of venture funding from Flagship Pioneering on May 7, 2004. The company is a manufacturer of new therapeutics using viral protein evolution.
Averto Medical: The company raised $30.5 million of Series A-1 venture funding in a deal led by Cormorant Asset Management on May 7, 2024, putting the company’s pre-money valuation at $30 million. Venrock, LifeSci Venture Partners Crown Venture Fund, and other undisclosed investors also participated in the round. The company is a manufacturer of a medical device that facilitates minimally invasive colorectal tumor removal.
Iambic Therapeutics: The company raised $29.8 million of Series B-2 venture funding from undisclosed investors on May 6, 2024, putting the company’s pre-money valuation at $343.4 million. The company is a developer of an AI-driven drug-discovery platform.
Holobeam Technologies: The company raised $16 million of venture funding from undisclosed investors on May 6, 2024. The company is a developer of a cancer cell destruction technology designed to offer diagnostic imaging and treatment of cancer.
Opmed.ai: The company raised $15 million of Series A venture funding in a deal led by NFX and Grove Ventures on May 6, 2024. Secret Chord, Unbox ventures and Sir Ronald Cohen also participated in the round. The company is a developer of healthcare automation software intended to reassign resources and staff in dynamic response to changing situations.
Neurable: The company raised $13 million of venture funding in a deal led by Ultratech Capital Partners on May 7, 2024. Trac, Pace Ventures, Metaplanet Holdings and Bramalea Partners also participated in the round. The company is a developer of brain-computer interfaces designed to translate activity into actionable insights.
Phenomix Sciences: The company raised $5 million of venture funding from undisclosed investors on May 6, 2024. The company is a developer of data analysis platform designed for precision medicinal research on obesity management.
Arthromeda: The company raised $2.3 million of venture funding in the form of convertible debt from Thornapple River Capital and other undisclosed investors on May 6, 2024. The company is a medical device business focused on developing technologies to improve surgical outcomes for patients undergoing joint replacement procedures.
Catena Biosciences: The company is in the process of raising Series A venture funding on May 10, 2024. The company is a developer of an advanced protein coupling technology designed to cure autoimmune disorders.
|
